Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
The costs will be those associated in the main with the EB phase 3 study that starts in January 2017 (I believe). In light of this time frame, I suspect that some of these costs will have been incurred already (possibly inc. an up front fee) On that basis, I would think the figure probably can be taken as representative of cash burn at this point in time.
Thanks mytrader It's mentioned under 'interims' (first page second bullet) of the research note.
Alfacomp - I believe it's in the half yearly report. I'll try and dig it out unless anyone else has it immediately to hand!
The problem I think we have is that with such a high cash burn (€500k per month) and nothing to show on the other side, the share is just slipping by a commensurate amount. I fear that unless Michele Bellandi (Chief Commercial Officer) can produce some news outside of the ongoing clinical trials, we will simply slip further. With his background in sales and marketing, I would have expected something from his department (assuming its not just him!).
We know their cash burn is £500k a month, but do we know what proportion of this is salaries?
Thanks Kev4 Whilst it is good that funding options are being considered this early into the cycle, I hope it doesn't hang over us in 2017. TI
Thanks Cookie Someone was suggesting either here or on ADVFN that a competitor in Episalvan's marketplace was bought out at the start of their Phase 3 trial. Is this usual and could you see the same happening here? In light of your last comment regarding the size of the potential market, it is surprising that the AP102 news failed to have any effect on the share price. Have a great weekend TI
Hi all Do we think the AP102 Orphan Drug Designation is the last news for 2016? I suspect the EMA ODD will be in the new year along with news of the start of the Episalvan Phase 3 trials. Is there the potential for a partnership deal with any of the above or Imlan any time soon? Just interested in any views....to offset the tedium! Thanks in advance TI
Hi equitrder Point taken. However, I personally would be more concerned if Wiley, Nealon (and to some extent) Friel didn't hold any stock. I suspect for each of the above, the success or failure of this venture will be life changing. OK, it would be a good signal to the market if Stratford were to buy in too, but this would be a token gesture for a man who has more money than he needs.
Thanks Kev4. Still a way to go on this one. Bring on the EB P3.
Morning Early Bird What does: 'prepare to bring AP102 into the clinic next year'. Does this merely mean start trials? Thanks in advance!
Yes - he was there before Amryt. Judging by Innocoll's share price crash, they're probably hoping he rings them!
What is the relevance to Amryt please?
I have always found it odd that a few thousand pounds worth of trades can knock millions off a company's valuation! The recent movements have been entirely disproportional to the trading activity.
How is commenting on some trades 'pumping'?
They are giving a presentation at the offices Shard Capital next Tuesday (I don't have a link, but mentioned on ADVFN). That will be an opportunity to update investors and I wouldn't be surprised if it's timed to coincide with news. Shard began coverage of Amryt in April 2016.
Thanks ShrewDEds. Forgive my subdued response to your earlier post! Getting a bit impatient with this lot now. I've been holding for 3+ years largely on promises of better times ahead but only to try and recover my £27k overall investment (in oil and gas mainly). To say I've heard it all before is an understatement! GOOD NEWS is all that will do it I feel. Here's hoping for some (and that Friel can deliver on at least one promise in my (and his) lifetime). All the very best. TI
Thanks. Found 'her' now (Nicola not Nicolas). Still not sure it's a qualified support level.
Wondering why anyone thinks this is a support level. It dropped Friday and its not been tested yet with any selling volume! Can I ask who this Nicolas Duke is please?
The Dublin office is in fact the office of Raglan Capital which is owned by Cathal Friel. I suspect the business is registered there but I doubt this is where any staff are based.